U.S. Markets closed
  • S&P Futures

    4,142.00
    -4.75 (-0.11%)
     
  • Dow Futures

    32,739.00
    -18.00 (-0.05%)
     
  • Nasdaq Futures

    13,217.00
    -11.75 (-0.09%)
     
  • Russell 2000 Futures

    1,920.00
    -1.80 (-0.09%)
     
  • Crude Oil

    89.07
    +0.06 (+0.07%)
     
  • Gold

    1,790.70
    -0.50 (-0.03%)
     
  • Silver

    19.85
    +0.01 (+0.04%)
     
  • EUR/USD

    1.0183
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    2.8400
    +0.1640 (+6.13%)
     
  • Vix

    21.15
    -0.29 (-1.35%)
     
  • GBP/USD

    1.2071
    +0.0001 (+0.01%)
     
  • USD/JPY

    135.3320
    +0.3620 (+0.27%)
     
  • BTC-USD

    23,292.88
    +331.96 (+1.45%)
     
  • CMC Crypto 200

    542.41
    +7.18 (+1.34%)
     
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • Nikkei 225

    28,226.88
    +51.01 (+0.18%)
     

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

·1 min read
  • Portage Biotech Inc (NASDAQ: PRTGacquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3.

  • The platform was acquired through Portage's iOx Therapeutics Ltd. subsidiary from the founding equity holders for 1.07 million Portage shares.

  • Additionally, a payment of $25 million would be triggered upon achieving a certain clinical milestone in the PORT-2 or PORT-3 programs.

  • Tarus acquisition is highly favorable for Portage's long-term prospects, even though HC Wainwright did not factor any revenue from these assets into the valuation.

  • Related: Portage Biotech Bolsters Pipeline With Acquisition Of Four Adenosine Pathway-Targeting Candidates.

  • The company expects preliminary data from these programs by the end of 2022 and early 2023, respectively.

  • HC Wainwright says that it has solely modeled sales of PORT-2 in melanoma, starting in 2025, equivalent to peak sales of $270 million by 2035.

  • Price Action: PRTG shares are up 5.28% at $9.87 during the market session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.